Company Mateon Therapeutics, Inc. Other OTC
Equities
MATN
US57667K1097
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 19-04-21 |
Director of Finance/CFO | 57 | 19-06-30 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 20-01-05 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 20-05-10 |
Saran Saund
PRN | Corporate Officer/Principal | 66 | 19-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Steven King
BRD | Director/Board Member | 59 | 20-05-10 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 20-05-10 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 19-04-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 399,684,128 | 180,543,314 ( 45.17 %) | 0 | 45.17 % |
Company contact information
![address Mateon Therapeutics, Inc.(MATN)](https://cdn.zonebourse.com/static/address/32411254.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+21.45% | 127B | |
+24.35% | 117B | |
+25.44% | 27.67B | |
-18.80% | 20.33B | |
-15.17% | 16.79B | |
-16.12% | 15.63B | |
+12.83% | 14.84B | |
-47.10% | 14.65B | |
+57.89% | 14.43B |